Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Sopharma AD-Sofia's accounts receivables for the quarter that ended in Jun. 2026 was €258 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Sopharma AD-Sofia's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 64.56.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Sopharma AD-Sofia's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was €-0.36.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Sopharma AD-Sofia's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Sopharma AD-Sofia's accounts receivable are only considered to be worth 75% of book value:
Sopharma AD-Sofia's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Sopharma AD-Sofia Accounts Receivable Related Terms
Sopharma AD-Sofia Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (FRA:3JR) has a Accounts Receivable of €258 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Accounts Receivable too high?
Sopharma AD-Sofia's current Accounts Receivable is €258 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Accounts Receivable compare to MCK and COR?
Sopharma AD-Sofia's Accounts Receivable of €258 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Distribution company?
A good Accounts Receivable depends on the Medical Distribution industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Accounts Receivable is €258 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.08, compared to a current price of €2.42 — trading 124.1% above its estimated fair value. The current Accounts Receivable is €258 Mil. Sopharma AD-Sofia's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current Accounts Receivable is €258 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued.
The current stock price of €2.42 is trading 124.1% above its estimated GF Value™ of €1.08.
GuruFocus considers Sopharma AD-Sofia to be Significantly Overvalued.
Key valuation signals for FRA:3JR:
Accounts Receivable: €258 Mil
GF Value™: €1.08 vs. price of €2.42 (124.1% above fair value)
No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
60GF Score
Get the complete analysis for FRA:3JR
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3JR has been successfully added to your 
